Roche signs agreement to acquire 89bio in $2.4bn deal
The deal is anticipated to close in Q4 2025, subject to customary closing conditions.
deal
CapVest to buy control of generics giant Stada in €10bn deal
Immedica to buy Marinus Pharmaceuticals for $151m
Investors optimistic about continued biotech and medtech IPO resurgence in 2025
AlloVir and Kalaris enter merger to advance retinal disease therapies
Sanofi’s $17bn sale of Opella to US investors advances following government deal
Sanofi signs radioligand therapy licensing deal for rare cancers
UCB to divest China neurology and allergy business for $680m
